Assistant Professor of GI Oncology @EinsteinMed @MontefioreNYC via @slusom and @USJLiban. Views are my own.
New York, NY
Joined November 2009
- Tweets12.4K
- Following1.9K
- Followers1.9K
- Likes7.9K
Fernand Bteich, MD, MS retweeted
Preliminary clinical results of QTX3034, an oral G12D-preferring KRAS inhibitor with cetuximab ± mFOLFOX6 in KRASG12D-mCRC
#ESMO26 #ESMOAmbassadors
👉ORR: 25% vs 50%, DCR: 75 vs 90%
👉 no new safety signals
🧐Supports the combination with CTx
@myESMO @ASCO
Fernand Bteich, MD, MS retweeted
Steroid free antiemetic regimen in Phase III trial!
Phase III (DESCEND, n=644): with NEtupitant/palonosetron (NEPA), a fixed-dose oral com-
bination, improves CINV control + olanzapine as the shared backbone, both cutting dexamethasone to a single 6mg dose on day 1 and dropping it entirely were noninferior to standard 4-day DEX for CINV in highly emetogenic chemo.
CR (complete response: no emesis, no rescue meds), 0-120h: 72.4% standard vs 72.2% DEX-sparing vs 70.1% DEX-free. Both met noninferiority, confirmed per-protocol.
Steroid toxicity (insomnia, agitation, hiccups) dropped significantly in both reduced-DEX arms. @KlugmanMaddie
Meng et al, JCO 2026
doi.org/10.1200/JCO.26-01029
#oncology #breastcancer #CINV
With #Daraxonrasib becoming more available for #PancreaticCancer, I wanted to make the treatment process a bit easier to navigate. Here is a handy infographic for doctors and patients alike. Please feel free to share! 🩺📈
Fernand Bteich, MD, MS retweeted
A p-value with a double-digit negative exponent is such an incredible (and richly deserved) flex #ASCO26
Fernand Bteich, MD, MS retweeted
Incredible #ASCO26 moment.
Dr. Brian Wolpin, presenter of the daraxonrasib study, received a standing ovation DURING his talk after he stated the survival benefit for PDAC patients. It was sustained. Cheering. I have never see anything like it in the middle of a talk. $RVMD
Coming very soon. 😉
Dar-axonrasib dared to go where all else failed!
Amazing moment to witness reaching this ultimate Holy Grail of oncology- through amazing chemical biology doubling overall survival for pts w advanced pancreatic cancer!
Personally so excited that through the generous RevMed EAP program our patients in the Bronx will have access to this transformational drug imminently!
@fernandbteich
#ASCO26
Fernand Bteich, MD, MS retweeted
Il m’a fait chialer 😭
Wawrinka est le symbole du champion qui n’avait pas sa place parmi les légendes, et qui a déplacé des montagnes et traversé des déserts, pour marquer son sport et aller plus loin que ses rêves.
Un exemple.
Un mec bien.
Simple, vrai, fort.
Adieu papy ❤️
Fernand Bteich, MD, MS retweeted
As noted by others, the $RVMD dara mOS in 2nd line PDAC is better than mOS for current first-line regimens.
Fernand Bteich, MD, MS retweeted
I remember years ago in pancreatic cancer trials you were realistically looking for 1 to 2 months improvement in survival (at best) in pancreatic cancer trials. Bravo $RVMD.👏
Fernand Bteich, MD, MS retweeted
-Papá, ¿tan bueno era Nadal en tierra batida?
-Muchísimo, hijo, no se ha visto nunca nada igual.
-¿Tan difícil era ganarle un partido?
-Los rivales celebraban ganarle un simple punto, hijo. Era una locura.
Fernand Bteich, MD, MS retweeted
💙 March is Colorectal Cancer Awareness Month.
Dr. Fernand Bteich @fernandbteich @MontefioreNYC reviews evolving strategies for KRAS-mutated metastatic CRC, including advances in molecular testing, targeted therapies, and overcoming resistance.
🎥 Watch on #Vumedi: tinyurl.com/59j2ufnp
#ColorectalCancer #GIOncology #CancerAwareness #PrecisionOncology
Fernand Bteich, MD, MS retweeted
HISTORIC.
22 year old Carlos Alcaraz defeats 24-time GS champ Novak Djokovic 2-6, 6-2, 6-3, 7-5 to win the #AusOpen for the 1st time and become the YOUNGEST EVER player to complete the career Grand Slam.
Already one of the best players ever.
What a time to be alive.
